Gaining Green

Biotech Voaltile Stocks: Novavax (NASDAQ:NVAX), Conatus Pharmaceuticals Inc (NASDAQ:CNAT), Seattle Genetics (NASDAQ:SGEN), RXi Pharmaceuticals Corp (NASDAQ:RXII)

Novavax, Inc. (NASDAQ:NVAX)’s shares dropped 8.44% and closed at $4.34. The company on June 23 announce that it has been recognized as one of The Washington Post Top Workplaces. The Washington Post Top Workplaces are determined based solely on employee feedback. The employee survey was conducted by WorkplaceDynamics, LLP, a leading research firm on organizational health and employee engagement. Novavax, Inc. (NASDAQ:NVAX), weekly performance is -3.70%. On last trading day company shares ended up $4.68. Analysts mean target price for the company is $11.00. Novavax, Inc. (NASDAQ:NVAX), distance from 50-day simple moving average (SMA50) is 3.26%.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT),, a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced that it will relocate the company’s corporate headquarters to a new leased facility in northern San Diego at 16745 W Bernardo Drive, Suite 200, San Diego, CA 92127. All Conatus phone numbers will change as a result of the relocation. Email addresses will not change. Conatus Pharmaceuticals Inc (NASDAQ:CNAT), advanced 2.09% in last trading session and ended the day on $7.80. return on assets is -22.50%. Conatus Pharmaceuticals Inc (NASDAQ:CNAT), quarterly performance is 4.84%.

Seattle Genetics, Inc. (NASDAQ:SGEN), was upgraded by Zacksfrom a “neutral” rating to an “outperform” rating in a note issued to investors on Monday. The firm currently has a $42.10 target price on the stock. Zacks‘s price objective suggests a potential upside of 18.76% from the company’s current price. Seattle Genetics, Inc. (NASDAQ:SGEN), shares moved up 0.79% in last trading session and was closed at $35.74, while trading in range of $34.88 – 37.86. Seattle Genetics, Inc. (NASDAQ:SGEN), year to date (YTD) performance is -10.40%.

RXi Pharmaceuticals Corp (NASDAQ:RXII), a biotechnology company focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently appointed Dr. Peter Campochiaro, a prominent researcher, clinician, and educator that sees patients at the Wilmer Eye Institute at Johns Hopkins. RXi Pharmaceuticals Corp (NASDAQ:RXII), ended the last trading day at $2.56 Company weekly volatility is calculated as 7.49% and price to cash ratio as 2.99. RXi Pharmaceuticals Corp (NASDAQ:RXII), showed a negative weekly performance of 14.09